{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T05:13:35Z","timestamp":1773724415588,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","ajconline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.amjcard.2015.05.038","type":"journal-article","created":{"date-parts":[[2015,6,6]],"date-time":"2015-06-06T12:37:17Z","timestamp":1433594237000},"page":"694-698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study)"],"prefix":"10.1016","volume":"116","clinical-trial-number":[{"clinical-trial-number":"nct00382460","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Amit V.","family":"Khera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arman","family":"Qamar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina A.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Rader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2015.05.038_bib1","first-page":"259","article-title":"Human resistin: found in translation from mouse to man","volume":"22","author":"Schwartz","year":"2011","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.amjcard.2015.05.038_bib2","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1373\/clinchem.2004.032482","article-title":"Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin","volume":"50","author":"Meier","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.amjcard.2015.05.038_bib3","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1161\/01.CIR.0000155620.10387.43","article-title":"Resistin is an inflammatory marker of atherosclerosis in humans","volume":"111","author":"Reilly","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2015.05.038_bib4","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1210\/jc.2007-2735","article-title":"Plasma resistin levels and risk of myocardial infarction and ischemic stroke","volume":"93","author":"Weikert","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.amjcard.2015.05.038_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2013.11.069","article-title":"Leptin and coronary heart disease: a systematic review and meta-analysis","volume":"233","author":"Chai","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2015.05.038_bib6","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1161\/hc5001.101061","article-title":"Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS)","volume":"104","author":"Wallace","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2015.05.038_bib7","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0002-9149(02)02201-4","article-title":"Design of the pravastatin or atorvastatin evaluation and infection therapy (PROVE IT)-TIMI 22 trial","volume":"89","author":"Cannon","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2015.05.038_bib8","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2015.05.038_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2015.05.038_bib10","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35053000","article-title":"The hormone resistin links obesity to diabetes","volume":"409","author":"Steppan","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.amjcard.2015.05.038_bib11","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2337\/diabetes.50.10.2199","article-title":"Resistin\/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans","volume":"50","author":"Savage","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.amjcard.2015.05.038_bib12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.7326\/0003-4819-149-5-200809020-00005","article-title":"Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women","volume":"149","author":"Heidemann","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2015.05.038_bib13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2337\/dc08-1625","article-title":"Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts","volume":"32","author":"Chen","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2015.05.038_bib14","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1172\/JCI37273","article-title":"Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice","volume":"119","author":"Qatanani","year":"2009","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.amjcard.2015.05.038_bib15","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.cmet.2014.01.013","article-title":"Adenylyl cyclase-associated protein 1 is a receptor for human resistin and mediates inflammatory actions of human monocytes","volume":"19","author":"Lee","year":"2014","journal-title":"Cell Metab"},{"key":"10.1016\/j.amjcard.2015.05.038_bib16","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/eurheartj\/ehu085","article-title":"Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials","volume":"35","author":"Stein","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2015.05.038_bib17","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.jacc.2011.11.064","article-title":"Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin\/kexin type 9","volume":"59","author":"Melone","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2015.05.038_bib18","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2015.05.038_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.atherosclerosis.2006.05.039","article-title":"Resistin, acute coronary syndrome and prognosis results from the AtheroGene study","volume":"193","author":"Lubos","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2015.05.038_bib20","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1253\/circj.72.1249","article-title":"Plasma resistin associated with myocardium injury in patients with acute coronary syndrome","volume":"72","author":"Chu","year":"2008","journal-title":"Circ J"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914915014228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914915014228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T18:41:29Z","timestamp":1668624089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914915014228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0002914915014228"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2015.05.038","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study)","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2015.05.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}